It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Take a look at some of Wednesday's midday movers.
Check out which companies are making headlines before the bell.
Take a look at Tuesday's midday movers:
Want to avoid taking a hit on your portfolio because of troubles in Washington? Cramer found one sector that will be a shelter from the storm.
It’s time for the Lightning Round! Jim Cramer makes the call on viewers' favorite stocks.
ImmunoGen president and CEO Daniel Junius discusses the potential for its cancer treatment Kadcyla, and whether investors should be concerned about toxicity problems in some of its drug trials.
With shares tumbling more than 10% in only a month, what should you do with ImmunoGen?
The trick to successful investing is knowing when to take profits and walk away. In this case, Cramer says it’s time.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
Earnings season kicks off in the week ahead and these quarterly reports could really make or break the bulls.
At least three companies are on the cutting edge of new treatments for perhaps the most feared disease known to mankind.
Dan Junius, ImmunoGen CEO, discusses which drugs are in the company's pipeline, and weighs in on the outlook for the company, with Mad Money's Jim Cramer.
WALTHAM, Mass.-- ImmunoGen Inc. on Friday said that its fiscal first quarter loss widened 29 percent, as it spent more money developing its experimental drugs.
Check out which companies are making headlines after the bell Wednesday:
Daniel Junius, CEO of Immunogen, discusses drugs the company is developing.
Take a look at some of Monday's midday movers:
Here are some snap biotech and drug stock judgments after a weekend spent at the American Society of Clinical Oncology annual meeting.
Cramer makes the call on viewers' favorite stocks.
Daniel Junius talks to Cramer about the drug’s recent trial, which was good news for the company’s stock, and when the FDA could get it for approval.